| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.
|
J Clin Oncol
|
2012
|
1.86
|
|
2
|
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.
|
Mol Cell Biol
|
2007
|
1.62
|
|
3
|
Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts.
|
Int J Cancer
|
2004
|
1.61
|
|
4
|
Management of spermatic cord tumors: a rare urologic malignancy.
|
Ther Adv Urol
|
2012
|
1.56
|
|
5
|
MR imaging of renal masses: correlation with findings at surgery and pathologic analysis.
|
Radiographics
|
2008
|
1.54
|
|
6
|
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.
|
Cancer Res
|
2013
|
1.49
|
|
7
|
Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer.
|
J Urol
|
2006
|
1.48
|
|
8
|
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2.
|
Mol Cell
|
2007
|
1.47
|
|
9
|
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer.
|
J Oncol Pract
|
2014
|
1.47
|
|
10
|
Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy.
|
J Urol
|
2003
|
1.45
|
|
11
|
Commentary on "identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array." Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study
|
Urol Oncol
|
2014
|
1.42
|
|
12
|
Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
|
Cancer Res
|
2004
|
1.28
|
|
13
|
MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).
|
Cancer Res
|
2007
|
1.20
|
|
14
|
The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection.
|
J Urol
|
2003
|
1.10
|
|
15
|
c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells.
|
Cancer Res
|
2007
|
1.09
|
|
16
|
Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
|
Cancer Lett
|
2006
|
1.05
|
|
17
|
Stromally expressed c-Jun regulates proliferation of prostate epithelial cells.
|
Am J Pathol
|
2007
|
0.97
|
|
18
|
Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system.
|
Am J Surg Pathol
|
2012
|
0.97
|
|
19
|
Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.
|
Clin Cancer Res
|
2009
|
0.97
|
|
20
|
Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy.
|
Prostate
|
2011
|
0.96
|
|
21
|
Models of care and NCCN guideline adherence in very-low-risk prostate cancer.
|
J Natl Compr Canc Netw
|
2013
|
0.95
|
|
22
|
Smaller prostate gland size and older age predict Gleason score upgrading.
|
Urol Oncol
|
2011
|
0.94
|
|
23
|
Men with organ-confined prostate cancer and positive surgical margins develop biochemical failure at a similar rate to men with extracapsular extension.
|
Urology
|
2011
|
0.92
|
|
24
|
Commentary on "integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer." Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T, Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.: Cancer Cell 2013;23(2):159-70.
|
Urol Oncol
|
2014
|
0.92
|
|
25
|
Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells.
|
Int J Cancer
|
2009
|
0.89
|
|
26
|
Inhibition of TNF-α improves the bladder dysfunction that is associated with type 2 diabetes.
|
Diabetes
|
2012
|
0.88
|
|
27
|
Novel targeted pro-apoptotic agents for the treatment of prostate cancer.
|
J Urol
|
2007
|
0.86
|
|
28
|
A close surgical margin after radical prostatectomy is an independent predictor of recurrence.
|
J Urol
|
2012
|
0.86
|
|
29
|
Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
|
Clin Cancer Res
|
2007
|
0.85
|
|
30
|
Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia.
|
Differentiation
|
2011
|
0.83
|
|
31
|
Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
|
J Urol
|
2004
|
0.80
|
|
32
|
Surgical management of scrotal lymphedema using local flaps.
|
Ann Plast Surg
|
2007
|
0.77
|
|
33
|
Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation.
|
Mol Cancer Res
|
2013
|
0.77
|
|
34
|
Commentary on "ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients." Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC, Orkin SH, Li Z, Division of Hematology and Oncology, Boston Children's Hospital, Boston, MA, USA.: Genes Dev 2013;27(6):683-98.
|
Urol Oncol
|
2014
|
0.77
|
|
35
|
Commentary on "the E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity." Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA, Signal Transduction Program, Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA.: Cancer Cell 2013;23(6):332-46.
|
Urol Oncol
|
2014
|
0.75
|
|
36
|
Commentary on "randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients." Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, Klotz L, Finelli A, Fleshner N, Vieth R, Department of Nutritional Sciences, University of Toronto, Ontario, Canada.: J Clin Endocrinol Metab 2013;98(4):1498-507 [Epub 2013 Mar 5].
|
Urol Oncol
|
2014
|
0.75
|
|
37
|
Editorial comment.
|
J Urol
|
2012
|
0.75
|
|
38
|
Commentary on "age-related alterations in T-lymphocytes modulate key pathways in prostate tumorigenesis." De Angulo A, Faris R, Cavazos D, Jolly C, Daniel B, DeGraffenried L, Department of Nutritional Sciences, Dell Pediatric Research Institute, University of Texas, Austin, TX, USA.: Prostate 2013;73(8):855-64 [Epub 2013 Mar 26].
|
Urol Oncol
|
2014
|
0.75
|
|
39
|
Urothelial mucosal malformation: a rare cause for ureteropelvic junction obstruction.
|
Pediatr Dev Pathol
|
2006
|
0.75
|
|
40
|
Overcoming resistance to trail-induced apoptosis in prostate cancer by regulation of c-FLIP.
|
Methods Enzymol
|
2008
|
0.75
|